PSI Advisors’s Sage Therapeutics SAGE Stock Holding History

PSI Advisors’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-85	Closed	-$6K	–	492
2019 Q4	$6K	Buy	+85	New	+$10.5K	﹤0.01%	530

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

PSI Advisors's SAGE Position: Q1 2020 in Review

PSI Advisors sold out of Sage Therapeutics (SAGE) in Q1 2020, closing a stake of 85 shares — an estimated $6K sold.

PSI Advisors first reported a position in SAGE in Q4 2019 and held it in 1 quarter. The position peaked at $6K in Q4 2019. 229 funds tracked by Wall St. Rank hold SAGE as of Q1 2020.

PSI Advisors reported no remaining Sage Therapeutics position as of Q1 2020 after selling out during the quarter.
PSI Advisors sold 85 Sage Therapeutics shares in Q1 2020, an estimated $6K.
PSI Advisors first reported a position in Sage Therapeutics in Q4 2019 and held it in 1 quarter.
PSI Advisors's Sage Therapeutics position peaked at $6K in Q4 2019.
229 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2020.

Based on PSI Advisors's 13F filing for Q1 2020, filed 15 May 2020.